Genetic Aberrations in Prostate Carcinoma Detected by Comparative Genomic Hybridization and Microsatellite Analysis: Association with Progression and Angiogenesis

Prostate

Volumn 59, Issue 1, 2004, Pages 43-58

  Strohmeyer, Dagmar M ^a,f   Berger, Andreas P ^a   Moore II, Dan H ^b   Bartsch, Georg ^a   Klocker, Helmut ^a   Carroll, Peter R ^c   Loening, Stefan A ^d   Jensen, Ronald H ^e  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUMBOLDT UNIVERSITY   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Angiogenesis; CGH; Genetic alterations; Microsatellite analysis; Progression; Prostate carcinoma

Indexed keywords

ANGIOGENESIS; ARTICLE; CANCER RECURRENCE; CELL DENSITY; CHROMOSOME 10; CHROMOSOME 10Q; CHROMOSOME 13; CHROMOSOME 13Q; CHROMOSOME 15; CHROMOSOME 16; CHROMOSOME 2; CHROMOSOME 2Q; CHROMOSOME 5; CHROMOSOME 6; CHROMOSOME 7Q; CHROMOSOME 8; CHROMOSOME 8Q; CHROMOSOME XQ; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DNA DETERMINATION; FOLLOW UP; GENE LOCUS; GENETIC ASSOCIATION; HUMAN; MALE; MICROSATELLITE MARKER; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; DNA, NEOPLASM; GENE DOSAGE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICROSATELLITE REPEATS; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 1642404463     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20028     Document Type: Article

References (71)

1. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998;160:2428-2434.
2. Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes Chromosomes Cancer 1994;11:153-162.
3. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-347.
4. Joos S, Bergerheim US, Pan Y, Matsuyama H, Bentz M, du Manoir S, Lichter P. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995;14:267-276.
5. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Sokhom SP, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-3102.
6. Sattler HP, Rohde V, Bonkhoff H, Zwergel T, Wullich B. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer. Prostate 1999;39:79-86.
7. Cher ML, Lewis PE, Banerjee M, Hurley PM, Sakr W, Grignon DJ, Powell IJ. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian Americans. Clin Cancer Res 1998;4:1273-1278.
8. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinoma. Am J Pathol 1989;153:141-148.
9. Zitzelsberger H, Kulka U, Lehmann L, Walch A, Smida J, Aubele M, Lorch T, Hofler H, Bauchinger M, Werner M. Genetic heterogeneity in a prostatic carcinoma and associated prostatic intraepithelial neoplasia as demonstrated by combined use of laser-microdissection, degenerate oligonucleotide primed PCR, and comparative genomic hybridization. Virchows Arch 1998;433:297-304.
10. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406.
11. Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, Tanke HJ, Schroder FH, van Dekken H. Identification of genetic markers for prostatic cancer progression. Lab Invest 2000;80:931-942.
12. Verhagen PC, Zhu XL, Rohr LR, Cannon-Albright LA, Tavtigian SV, Skolnick MH, Brothman AR. Microdissection, DOP-PCR, and comparative genomic hybridization of paraffin-embedded familial prostate cancers. Cancer Genet Cytogenet 2000;122:43-48.
13. Chu LW, Troncoso P, Johnston DA, Liang JC. Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer. Genes Chromosomes Cancer 2003;36(3):303-312.
14. Kim SH, Kim MS, Jensen RH. Genetic alterations in microdissected prostate cancer cells by comparative genomic hybridization. Prostate Cancer Prostatic Dis 2000;3(2):110-114.
15. Kasahara K, Taguchi T, Yamasaki I, Kamada M, Yuri K, Shuin T. Detection of genetic alterations in advanced prostate cancer by comparative genomic hybridization. Cancer Genet Cytogenet 2002;137(1):59-63.
16. Beheshti B, Vukovic B, Marrano P, Squire JA, Park PC. Resolution of genotypic heterogeneity in prostate tumors using polymerase chain reaction and comparative genomic hybridization on microdissected carcinoma and prostatic intraepithelial neoplasia foci. Cancer Genet Cytogenet 2002;137(1):15-22.
17. Wolter H, Trijic D, Gottfried HW, Mattfeldt T. Chromosomal changes in incidental prostatic carcinomas detected by comparative genomic hybridization. Eur Urol 2002;41(3):328-334.
18. Wolter H, Gottfried HW, Mattfeldt T. Genetic changes in stage pT2N0 prostate cancer studied by comparative genomic hybridization. BJU Int 2002;89(3):310-316.
19. Haapala K, Rokman A, Palmberg C, Hyytinen ER, Laurila M, Tammela TL, Koivisto PA. Chromosomal changes in locally recurrent, hormone-refractory prostate carcinomas by karyotyping and comparative genomic hybridization. Cancer Genet Cytogenet 2001;131(1):74-78.
20. Rokman A, Koivisto PA, Matikainen MP, Kuukasjarvi T, Poutiainen M, Helin HJ, Karhu R, Kallioniemi OP, Schleutker J. Genetic changes in familial prostate cancer by comparative genomic hybridization. Prostate 2001;46(3):233-239.
21. Zitzelsberger H, Engert D, Walch A, Kulka U, Aubele M, Hofler H, Bauchinger M, Werner M. Chromosomal changes during development and progression of prostate adenocarcinomas. Br J Cancer 2001;84(2):202-208.
22. El Gedaily A, Bubendorf L, Willi N, Fu W, Richter J, Moch H, Mihatsch MJ, Sauter G, Gasser TC. Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate 2001;46(3):184-190.
23. Kieser A, Weich HA, Brandner G, Marmé D, Kölch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;9:963-969.
24. Siemeister G, Weindel K, Mohrs K, Barleon B, Marring-Baren G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996;56:2999-2301.
25. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marmé D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995;270:25915-25919.
26. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
27. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
28. Folkman J. Clinical applications of angiogenesis research. N Engl J Med 1995;333:1757-1763.
29. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73:678-687.
30. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
31. Hall MC, Troncoso P, Pollack A, Zhau HY, Zagars GK, Chung LW, von Eschenbach AC. Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy. Urology 1994;44:869-875.
32. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997;33:38-45.
33. Bettencourt MC, Bauer JJ, Sesterhen IA, Connelly RR, Moul JW. CD 34 immunohistochemical assesment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998;160:459-465.
34. Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002;5(2):123-127.
35. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathological stage in Gleason sum 5 to 7 adenocarcinoma. Cancer 1997;79:772-779.
36. Strohmeyer D, Rössing C, Strauss F, Bauerfeind A, Kaufmann O, Loening SA. Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3-prostate cancer (PC). Prostate 2000;42:26-33.
37. Schroeder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TMN classification of prostate cancer. Prostate Suppl 1992;4:129-138.
38. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887.
39. Kuukasjarvi T, Tanner M, Pennanen S, Karhu R, Visakorpi T, Isola J. Optimizing DOP-PCR for universal amplification of small DNA samples in comperative genomic hybridization. Genes Chromosomes Cancer 1997;18:94-101.
40. Isola J, DeVries S, Chu L, Ghazvini S, Waldman F. Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. Am J Path 1994;145:1301-1308.
41. Isola J, Kallioniemi O-P, Chu L, Fuqua S, Hilsenbeck S, Osborne K, Waldman F. Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 1995;145:905-911.
42. Piper J, Rutovit D, Sudar D, Kallioniemi A, Kallioniemi OP, Waldman FM, Gray JW, Pinkel D. Computer image analysis of comparative genomic hybridization. Cytometry 1995;19:10-26.
43. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman F, Gray JW, Pinkel D. Optimizing comparative genomic hybridization foranalysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994;10:231-243.
44. Moore DH, Pallavicini M, Cher ML, Gray JW. A t-statistic for objective interpretation of comperative genomic hybridization (CGH) profiles. Cytometry 1997;28:183-190.
45. Gill P, Sparkes R, Pinchin R, Clayton T, Whitaker J, Buckleton J. Interpreting simple STR mixtures using allele peak areas. Forensic Sci Int 1998;91:41-53.
46. Sanchez-Cespedes M, Cairns P, Jen J, Sidransky D. Degenerate oligonucleotide-primed PCR (DOP-PCR): Evaluation of its reliability for screening of genetic alterations in neoplasia. Biotechniques 1998;25:1036-1038.
47. Aust DE, Willenbucher RF, Terdiman JP, Ferrell LD, Chang CG, Moore DH II, Molinaro A, Baretton GB, Loehrs U, Waldman FM. Chromosomal alterations in ulcerative colitis-related and sporadic colorectal cancers by comparative genomic hybridization. Hum Pathol 2000;31:109-114.
48. Kim SH, Godfrey T, Jensen RH. Whole genome amplification and molecular genetic analysis of DNA from paraffin-embedded prostate adenocarcinoma tumor tissue. J Urol 1999;162:1512-1518.
49. Melamed J, Einhorn JM, Ittmann MM. Allelic loss on chromosome 13q in human prostate carcinoma. Clin Cancer Res 1997;3:1867-1872.
50. Ittmann MM, Wieczorek R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum Pathol 1996;27(1):28-34.
51. Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu Y, Ekman P, Auer G, Bergerheim US. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 1998;16:481-487.
52. Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ. Distinct regions of allelic loss on 13q in prostate cancer. Cancer Res 1996;56:1142-1145.
53. Yin Z, Spitz MR, Babaian RJ, Strom SS, Troncoso P, Kagan J. Limiting the location of a putative human prostate cancer tumor suppressor gene at chromosome 13q14.3. Oncogene 1999;18:576-583.
54. Hyytinen ER, Frierson HF Jr., Boyd JC, Chung LW, Dong JT. Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 1999;25:108-114.
55. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord JE, Jonsson E. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 1997;75:758-761.
56. Ueda T, Emi M, Suzuki H, Komiya A, Akakura K, Ichikawa T, Watanabe M, Shiraishi T, Masai M, Igarashi T, Ito H. Identification of a I-cM region of common deletion on 13q14 associated with human prostate cancer. Genes Chromosomes Cancer 1999;24(3):183-190.
57. Latil A, Chene L, Mangin P, Fournier G, Berthon P, Cussenot O. Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. Prostate 2003;57(1):39-50.
58. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. Retinoblastoma gene mutations in primary human prostate cancer. Prostate 1995;27(6):314-320.
59. Brooks JD, Bova GS, Isaacs WB. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate 1995;26(1):35-39.
60. Phillips SM, Barton CM, Lee SJ, Morton DG, Wallace DM, Lemoine NR, Neoptolemos JP. Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis. Br J Cancer 1994;70(6):1252-1257.
61. Dong JT. Chromosomal deletions and tumor suppressor genes in prostate cancer. Cancer Metastasis Rev 2001;20(3-4):173-193.
62. Chen C, Frierson HF Jr., Haggerty PF, Theodorescu D, Gregory CW, Dong JT. An 800-kb region of deletion at 13q14 in human prostate and other carcinomas. Genomics 2001;77(3):135-144.
63. Srikantan V, Sesterhenn IA, Davis L, Hankins GR, Avallone FA, Livezey JR, Connelly R, Mostofi FK, McLeod DG, Moul JW, Chandrasekharappa SC, Srivastava S. Allelic loss on chromosome 6Q in primary prostate cancer. Int J Cancer 1999;84:331-335.
64. Verhagen PC, Hermans KG, Brok MO, van Weerden WM, Tilanus MG, de Weger RA, Boon TA, Trapman J. Deletion of chromosomal region 6q14-16 in prostate cancer. Int J Cancer 2002;102(2):142-147.
65. Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 1991;51:5449-5453.
66. Sheng ZM, Marchetti A, Buttitta F, Champeme MH, Campani D, Bistocchi M, Lidereau R, Callahan R. Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. Br J Cancer 1996;73:144-147.
67. Theile M, Seitz S, Arnold W, Jandrig B, Frege R, Schlag PM, Haensch W, Guski H, Winzer KJ, Barrett JC, Scherneck SA. Defined chromosome 6q fragment (at D6S310) harbors a putative TSG for breast cancer. Oncogene 1996;13:77-685.
68. Orphanos V, McGown G, Hey Y, Thorncroft M, Santibanez-Koref M, Russell SE, Hickey I, Atkinson RJ, Boyle J. M. Allelic imbalance of chromosome 6q in ovarian tumours. Br J Cancer 1995;71:666-669.
69. Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V, Minna JD, Gazdar AF. Alleotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 1998;21:308-319.
70. Bell DW, Jhanwar SC, Testa JR. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 1997;57:4057-4062.
71. Sandhu AK, Kaur GP, Reddy DE, Rane NS, Athwal RS. A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells. Oncogene 1996;12:247-252.1.